Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.7 USD | +0.75% | -6.25% | -6.57% |
Feb. 12 | Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
Feb. 07 | Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 34.39M 25.02M |
---|---|---|---|---|---|
Net income 2024 * | -18M -13.09M | Net income 2025 * | -23M -16.73M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.89
x | P/E ratio 2025 * |
-2.43
x | Employees | 32 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.98% |
Latest transcript on Acasti Pharma Inc.
1 day | +0.75% | ||
1 week | -6.25% | ||
Current month | -21.17% | ||
1 month | -21.74% | ||
3 months | +10.20% | ||
6 months | +12.50% | ||
Current year | -6.57% |
Managers | Title | Age | Since |
---|---|---|---|
Prashant Kohli
CEO | Chief Executive Officer | 52 | 21-07-31 |
Director of Finance/CFO | 52 | Jan. 04 | |
Carrie D'Andrea
CTO | Chief Tech/Sci/R&D Officer | 52 | 23-05-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
A. Davis
BRD | Director/Board Member | 57 | 23-10-09 |
Director/Board Member | - | 23-10-09 | |
Santosh Kottayil
BRD | Director/Board Member | - | 23-10-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 2.7 | +0.75% | 942 |
24-04-29 | 2.68 | -7.59% | 6,916 |
24-04-26 | 2.9 | -0.97% | 3,831 |
24-04-25 | 2.928 | +0.98% | 2,583 |
24-04-24 | 2.9 | +0.69% | 8,424 |
Delayed Quote Nasdaq, April 30, 2024 at 09:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.57% | 25.19M | |
+33.64% | 664B | |
+29.48% | 567B | |
-6.87% | 354B | |
+19.68% | 330B | |
+4.32% | 286B | |
+13.60% | 234B | |
+5.37% | 199B | |
-9.98% | 196B | |
-4.52% | 148B |
- Stock Market
- Equities
- ACST Stock